Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis

Daprodustat produced dose-dependent changes in hemoglobin over the first 4 weeks after switching from a stable dose of rhEPO as well as maintained hemoglobin target levels over 24 weeks.